OBJECTIVE: To observe the effect of Qiangli Dingxuan Tablet on cerebral hemodynamics and brainstem auditory evoked potentials in vertigo patients with posterior circulation ischemia. METHODS: A total of 120 vertigo pa...OBJECTIVE: To observe the effect of Qiangli Dingxuan Tablet on cerebral hemodynamics and brainstem auditory evoked potentials in vertigo patients with posterior circulation ischemia. METHODS: A total of 120 vertigo patients with posterior circulation ischemia were randomly divided into observation group and control group. 60 patients in the control group were treated with conventional western medicine. 60 patients in the observation group were treated with Qiangli Dingxuan Tablet on the basis of the control group. After 2 weeks of treatment, the improvement of vertigo(dizziness handicap inventory(DHI), dizziness handicap inventory(DHI)), the hemodynamic index(Basilar artery blood flow velocity(BA), left vertebroarterial artery(LVA), and the average blood flow velocity of right vertebroarterial artery(RVA)) and the changes in brain stem auditory evoked potential(BAEP) of two groups were observed. And statistical analysis was conducted for the clinical efficacy and adverse reactions during treatment of two groups. RESULTS: The total effective rate of the observation group was significantly higher than that of the control group(P < 0.05). The DHI and DARS scores of the two groups were significantly lower than those before treatment(P < 0.05), and the degree of reduction was more obvious in the observation group(P < 0.05). The levels of BA, LVA and RVA in the two groups were significantly higher than those before treatment(P < 0.05), and the levels of BA, LVA and RVA in the observation group were significantly higher than those in the control group(P < 0.05). The indexes of BAEP latency I, II, III and indexes of BAEP peak latency I-III, III-V, IV were obviously lower than those before treatment(P < 0.05). Besides, the decrease of BAEP index in the observation group was significantly lower than that in the control group(P < 0.05). No adverse reactions occurred during the treatment of the two groups. CONCLUSION: Qiangli Dingxuan Tablet is able to significantly improve the cerebral hemodynamics and brainstem auditory evoked potentials of patients with PCIV, and quickly relieve vertigo. It is safe and reliable and worthy of clinical application.展开更多
文摘OBJECTIVE: To observe the effect of Qiangli Dingxuan Tablet on cerebral hemodynamics and brainstem auditory evoked potentials in vertigo patients with posterior circulation ischemia. METHODS: A total of 120 vertigo patients with posterior circulation ischemia were randomly divided into observation group and control group. 60 patients in the control group were treated with conventional western medicine. 60 patients in the observation group were treated with Qiangli Dingxuan Tablet on the basis of the control group. After 2 weeks of treatment, the improvement of vertigo(dizziness handicap inventory(DHI), dizziness handicap inventory(DHI)), the hemodynamic index(Basilar artery blood flow velocity(BA), left vertebroarterial artery(LVA), and the average blood flow velocity of right vertebroarterial artery(RVA)) and the changes in brain stem auditory evoked potential(BAEP) of two groups were observed. And statistical analysis was conducted for the clinical efficacy and adverse reactions during treatment of two groups. RESULTS: The total effective rate of the observation group was significantly higher than that of the control group(P < 0.05). The DHI and DARS scores of the two groups were significantly lower than those before treatment(P < 0.05), and the degree of reduction was more obvious in the observation group(P < 0.05). The levels of BA, LVA and RVA in the two groups were significantly higher than those before treatment(P < 0.05), and the levels of BA, LVA and RVA in the observation group were significantly higher than those in the control group(P < 0.05). The indexes of BAEP latency I, II, III and indexes of BAEP peak latency I-III, III-V, IV were obviously lower than those before treatment(P < 0.05). Besides, the decrease of BAEP index in the observation group was significantly lower than that in the control group(P < 0.05). No adverse reactions occurred during the treatment of the two groups. CONCLUSION: Qiangli Dingxuan Tablet is able to significantly improve the cerebral hemodynamics and brainstem auditory evoked potentials of patients with PCIV, and quickly relieve vertigo. It is safe and reliable and worthy of clinical application.
文摘目的:基于循证药学,评价强力定眩片(胶囊)联合倍他司汀治疗眩晕的有效性和安全性。方法:计算机检索Embase、PubMed、the Cochrane Library、万方数据库、中国知网和中国生物医学文献数据库,纳入强力定眩片(胶囊)联合倍他司汀治疗眩晕的随机对照试验[研究组方案为强力定眩片(胶囊)联合倍他司汀治疗,对照组为单独使用倍他司汀治疗],检索时间为建库至2021年6月。由2名研究者提取资料、选取文献并评价纳入文献的偏倚风险后,采用Rev Man 5.4软件进行荟萃分析(Meta分析)。结果:共纳入11项随机对照试验,包括956例患者(研究组478例患者,对照组478例患者)。Meta分析结果显示,有效性方面,研究组患者的总有效率(OR=5.19,95%CI=3.33~8.10,P<0.00001)、显效率(OR=2.09,95%CI=1.57~2.78,P<0.00001)、痊愈率(OR=3.75,95%CI=1.86~7.55,P=0.0002)、眩晕症状评分(MD=-4.40,95%CI=-4.82~-3.98,P<0.00001)、眩晕障碍量表评分(MD=-10.57,95%CI=-11.92~-9.22,P<0.00001)、血浆黏度(MD=-0.25,95%CI=-0.32~-0.17,P<0.00001)、左椎动脉血流速度(MD=4.56,95%CI=3.38~5.74,P<0.00001)、右椎动脉血流速度(MD=4.37,95%CI=3.85~4.90,P<0.00001)、基底动脉血流速度(MD=3.49,95%CI=2.68~4.31,P<0.00001)、内皮素1水平(MD=-29.72,95%CI=-31.29~-28.15,P<0.00001)、降钙素基因相关肽水平(MD=6.21,95%CI=5.43~6.99,P<0.00001)和内皮素1/降钙素基因相关肽比值(OR=-2.01,95%CI=-2.38~-1.63,P<0.00001)均显著优于对照组,差异均有统计学意义;安全性方面,两组患者不良反应发生率比较,差异无统计学意义(OR=0.59,95%CI=0.14~2.53,P=0.47>0.05)。结论:现有证据表明,强力定眩片(胶囊)联合倍他司汀治疗眩晕安全、有效,较单独使用倍他司汀有显著优势。因纳入的研究数量和质量的限制,上述结论有待今后更多高质量随机对照试验予以验证。
